Human
Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
Moderna and Merck said Wednesday their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting melanoma, marking the first time a therapy of its kind has succeeded at that stage of testing. The news sent Moderna’s stock up more than 100% and lifted Merck shares as well, as investors bet on a new era for a company long defined by its Covid-19 vaccine.
4 hours ago










